PACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy (CRT) in patients with stage III, locally advanced, unresectable NSCLC


Paz-Ares L., Villegas A., Daniel D., Baz D. V. , Murakami S., Hui R., ...More

42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, Spain, 8 - 12 September 2017, vol.28 identifier

  • Publication Type: Conference Paper / Summary Text
  • Volume: 28
  • City: Madrid
  • Country: Spain